Discover McMaster's legacy of evidence-based medicine, clinical excellence, and innovation in research and patient care.
As artificial intelligence transforms the way physicians practise medicine globally, a McMaster researcher has launched a collaborative to advance the safe and effective use of AI in healthcare.
McMaster, the birthplace of evidence-based medicine, is well positioned to lead the development of standards for the use of AI, said EBAiM founder Bright Huo.
Physicians are using AI for everything from creating patient chart summaries to assisting with diagnoses. Despite its rapid uptake, the integration of AI in health care is fractured, inconsistent, and unregulated.
“There are all these innovations happening in AI but the work is siloed. This is a critical moment. The pieces are all there. We just need to put them all together.”
Helping people on six continents access comprehensive follow-up care after heart surgery is at the core of international trials led by a McMaster researcher.
The goal is to collect data from the most diverse study population possible so the results can benefit people all over the world who need specialized cardiac care, says Emilie Belley-Côté, a scientist at the Population Health Research Institute (PHRI) and associate professor of medicine at McMaster University.
“There are some patients in our trials who live in remote areas or face financial burdens that mean they are getting their blood levels tested much less frequently than what is recommended,” said Belley-Côté.
“We need to know how they’re impacted just as much as those patients who have easy access to health care.”
When the pandemic slowed much of the world down, a team of scientists at McMaster University moved quickly, leveraging prior research on tuberculosis vaccines to develop new inhaled COVID-19 vaccine candidates.
Today, a phase two clinical trial for the AeroVax inhaled COVID-19 vaccine is nearing completion with development costs at roughly $10 million — a mere sliver of the $50-100 million cost of typical vaccine development.
The desire to increase speed and lower cost of development of promising new health innovations was a shared ambition of many researchers at McMaster and heralded a culture shift that was the impetus behind the creation of NexusHealth – Canada’s first ever academically housed manufacturing lab.
Sign up to receive future communications from McMaster University
Health InnovationCIimate SolutionsCanada's Nuclear University
Contact Terms & Conditions Privacy Policy